Security
PepGen Inc. Common Stock · PEPG
PEPGNASDAQCommon stockCurrentCIK 1835597Updated Oct 6, 2026
PEPG price & chart
Loading TradingView…
NASDAQ:PEPG on TradingView ↗About the company
PepGen Inc. is a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, PepGen is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases.
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG ↗
PepGen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 8, 2025 to Discuss Your Rights - PEPG News provided by Levi & Korsinsky, LLP Aug 08, 2025, 08:45 ET Share this article Share to X Share this article Share to X NEW YORK , Aug. 8, 2025 /PRNewswire/ -- Le ↗
Recent filings
Results of Operations and Financial Condition · Regulation FD Disclosure · Other Events
Items 2.02, 7.01, 8.01, 9.01
10-Q filing
Submission of Matters to a Vote of Security Holders
Items 5.07
4 filing
4 filing
Show 5 more recent filings
EFFECT filing
Regulation FD Disclosure
Items 7.01, 9.01
S-3 filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 190,057,000Source | 170,234,000Source | 141,397,000Source | 102,242,000Source | 193,510,000Source | 156,295,000Source | 127,393,000Source | 207,000,000Source | 173,907,000Source | 150,883,000Source | 143,052,000Source | 217,440,000Source |
| Property, Plant and Equipment, NetUSD | 2,220,000Source | 3,901,000Source | 1,341,000Source | 2,489,000Source | 4,236,000Source | 1,565,000Source | 3,506,000Source | 4,440,000Source | 1,903,000Source | 3,716,000Source | 4,764,000Source | 3,335,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 142,775,000Source | 42,289,000Source | 22,764,000Source | 35,072,000Source | 66,085,000Source | 42,150,000Source | 43,633,000Source | 133,854,000Source | 60,514,000Source | 49,421,000Source | 80,774,000Source | 181,752,000Source |
| Assets, CurrentUSD | 166,206,000Source | 142,369,000Source | 120,329,000Source | 77,486,000Source | 164,778,000Source | 134,271,000Source | 101,047,000Source | 177,619,000Source | 150,963,000Source | 123,761,000Source | 112,678,000Source | 186,083,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,541,000Source | 3,512,000Source | 3,091,000Source | 2,833,000Source | 3,472,000Source | 1,968,000Source | 3,266,000Source | 2,396,000Source | 2,507,000Source | 3,570,000Source | 2,271,000Source | 4,273,000Source |
| Operating Lease, Right-of-Use AssetUSD | 19,711,000Source | 21,990,000Source | 17,914,000Source | 20,293,000Source | 22,540,000Source | 18,522,000Source | 20,866,000Source | 23,083,000Source | 19,121,000Source | 21,432,000Source | 23,620,000Source | 26,549,000Source |
| Other Assets, NoncurrentUSD | 372,000Source | 426,000Source | 265,000Source | 426,000Source | 1,956,000Source | 389,000Source | 426,000Source | 1,858,000Source | 372,000Source | 426,000Source | 1,990,000Source | 1,473,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 26,917,000Source | 32,779,000Source | 21,864,000Source | 31,084,000Source | 38,470,000Source | 22,315,000Source | 35,588,000Source | 28,001,000Source | 26,463,000Source | 32,263,000Source | 34,631,000Source | 37,809,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 7,000Source | 3,000Source | 7,000Source | 3,000Source | 3,000Source | 7,000Source | 3,000Source | 3,000Source | 7,000Source | 3,000Source | 2,000Source | 2,000Source |
| Retained Earnings (Accumulated Deficit)USD | -342,778,000Source | -249,221,000Source | -396,693,000Source | -324,752,000Source | -227,837,000Source | -378,881,000Source | -301,665,000Source | -199,502,000Source | -361,118,000Source | -271,463,000Source | -181,482,000Source | -102,856,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -25,000Source | 91,000Source | -117,000Source | -43,000Source | -75,000Source | -59,000Source | -22,000Source | -37,000Source | 11,000Source | 23,000Source | 34,000Source | -81,000Source |
| Stockholders' Equity Attributable to ParentUSD | 163,140,000Source | 137,455,000Source | 119,533,000Source | 71,158,000Source | 155,040,000Source | 133,980,000Source | 91,805,000Source | 178,999,000Source | 147,444,000Source | 118,620,000Source | 108,421,000Source | 179,631,000Source |
| Additional Paid in Capital, Common StockUSD | 505,936,000Source | 386,582,000Source | 516,336,000Source | 395,950,000Source | 382,949,000Source | 512,913,000Source | 393,489,000Source | 378,535,000Source | 508,544,000Source | 390,057,000Source | 289,867,000Source | 282,566,000Source |
| Liabilities and EquityUSD | 190,057,000Source | 170,234,000Source | 141,397,000Source | 102,242,000Source | 193,510,000Source | 156,295,000Source | 127,393,000Source | 207,000,000Source | 173,907,000Source | 150,883,000Source | 143,052,000Source | 217,440,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 12,642,000Source | 16,810,000Source | 9,005,000Source | 16,360,000Source | 22,107,000Source | 8,964,000Source | 20,431,000Source | 11,258,000Source | 12,646,000Source | 16,696,000Source | 17,531,000Source | 18,828,000Source |
| Operating Lease, Liability, CurrentUSD | 3,163,000Source | 3,071,000Source | 3,234,000Source | 3,140,000Source | 3,049,000Source | 3,210,000Source | 3,117,000Source | 3,026,000Source | 3,187,000Source | 3,094,000Source | 3,004,000Source | 5,553,000Source |
| Accounts Payable, CurrentUSD | 766,000Source | 5,930,000Source | 1,095,000Source | 856,000Source | 7,741,000Source | 622,000Source | 2,699,000Source | 1,480,000Source | 822,000Source | 1,752,000Source | 1,005,000Source | 1,362,000Source |
| Operating Lease, Liability, NoncurrentUSD | 14,275,000Source | 15,969,000Source | 12,859,000Source | 14,724,000Source | 16,363,000Source | 13,351,000Source | 15,157,000Source | 16,743,000Source | 13,817,000Source | 15,567,000Source | 17,100,000Source | 18,981,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 8,713,000Source | 7,809,000Source | 4,676,000Source | 12,364,000Source | 11,317,000Source | 5,132,000Source | 14,615,000Source | 6,752,000Source | 8,637,000Source | 11,850,000Source | 13,522,000Source | 11,913,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 163,700,000Source | 138,900,000Source | 117,200,000Source | 74,700,000Source | 161,300,000Source | 132,300,000Source | 97,800,000Source | 175,200,000Source | 148,500,000Source | 120,200,000Source | 110,400,000Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 300,000Source | 400,000Source | 300,000Source | 300,000Source | 300,000Source | 400,000Source | 1,400,000Source | 1,500,000Source | 1,200,000Source | 500,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,855,000Source | 3,432,000Source | 10,609,000Source | 11,457,000Source | 7,048,000Source | 4,763,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -18,426,000Source | -22,930,000Source | -81,635,000Source | -82,372,000Source | -68,997,000Source | -59,265,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -1,459,000Source | 17,149,000Source | -15,235,000Source | -37,668,000Source | -32,003,000Source | -3,755,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 125,000Source | 264,000Source | 497,000Source | 2,599,000Source | 3,755,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 1,518,000Source | 0Source | 107,979,000Source | 88,749,000Source | -189,000Source | 112,193,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -18,364,000Source | -5,788,000Source | 11,093,000Source | -31,353,000Source | -100,903,000Source | 48,857,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 0Source | 86,000Source | 82,000Source | 71,000Source | 2,702,000Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,377,000Source | 3,226,000Source | 3,313,000Source | 2,363,000Source | 2,855,000Source | 3,432,000Source | 10,609,000Source | 11,457,000Source | 7,048,000Source | 4,763,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 163,700,000Source | 138,900,000Source | 117,200,000Source | 74,700,000Source | 132,300,000Source | 97,800,000Source | 148,500,000Source | 120,200,000Source | 110,400,000Source | — |
| DepreciationUSD | — | — | — | — | — | — | 319,000Source | 388,000Source | 1,397,000Source | 1,505,000Source | 1,184,000Source | 493,000Source |
| General and Administrative ExpenseUSD | — | — | 5,231,000Source | 5,449,000Source | 6,417,000Source | 5,541,000Source | 5,938,000Source | 5,943,000Source | 22,569,000Source | 21,261,000Source | 16,640,000Source | 14,224,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 16,000Source | 0Source | 15,000Source | 0Source | 48,865Source | -617,000Source | 73,000Source | 3,706,000Source |
| Investment Income, InterestUSD | — | — | 634,000Source | 1,826,000Source | 1,093,000Source | 842,000Source | 1,250,000Source | 1,122,000Source | 4,017,000Source | 7,142,000Source | 6,400,000Source | 2,793,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,026,000Source | -21,384,000Source | -17,812,000Source | -23,087,000Source | -17,763,000Source | -30,202,000Source | -89,655,000Source | -89,981,000Source | -78,626,000Source | -69,104,000Source |
| Noncash Merger Related CostsUSD | — | — | — | — | — | — | 0Source | 11,000Source | — | 70,000Source | — | 134,000Source |
| Nonoperating Income (Expense)USD | — | — | 628,000Source | 1,787,000Source | 1,143,000Source | 845,000Source | 1,194,000Source | 1,119,000Source | 4,006,000Source | 7,141,000Source | 6,213,000Source | 2,903,000Source |
| Operating ExpensesUSD | — | — | 18,654,000Source | 23,171,000Source | 18,939,000Source | 23,932,000Source | 18,942,000Source | 31,321,000Source | 93,612,000Source | 97,739,000Source | 84,766,000Source | 68,301,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -6,000Source | -39,000Source | 50,000Source | 3,000Source | -56,000Source | -3,000Source | -11,000Source | -1,000Source | -187,000Source | 110,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 1,511,000Source | 0Source | — | 9,900,000Source | — | 114,267,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 27,000,000Source | 24,000,000Source | 79,000,000Source | 108,000,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | — | 217,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -18,654,000Source | -23,171,000Source | -18,939,000Source | -23,932,000Source | -18,942,000Source | -31,321,000Source | -93,612,000Source | -97,739,000Source | -84,766,000Source | -68,301,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -6,000Source | -39,000Source | 50,000Source | 3,000Source | -56,000Source | -3,000Source | -11,000Source | -1,000Source | -187,000Source | 110,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -18,026,000Source | -21,384,000Source | -17,796,000Source | -23,087,000Source | -17,748,000Source | -30,202,000Source | -89,606,000Source | -90,598,000Source | -78,553,000Source | -65,398,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 16,000Source | 0Source | 15,000Source | 0Source | 48,865Source | -617,000Source | 73,000Source | 3,706,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,026,000Source | -21,384,000Source | -17,812,000Source | -23,087,000Source | -17,763,000Source | -30,202,000Source | -89,655,000Source | -89,981,000Source | -78,626,000Source | -69,104,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.52Source | -0.66Source | -0.26Source | -0.7Source | -0.26Source | -0.92Source | -2.12Source | -2.85Source | -3.3Source | -4.42Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.52Source | -0.66Source | -0.26Source | -0.7Source | -0.26Source | -0.92Source | -2.12Source | -2.85Source | -3.3Source | -4.42Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 34,362,876Source | 32,581,542Source | 69,202,376Source | 32,748,646Source | 69,091,100Source | 32,674,720Source | 42,221,808Source | 31,583,073Source | 23,796,000Source | 15,639,728Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 34,362,876Source | 32,581,542Source | 69,202,376Source | 32,748,646Source | 69,091,100Source | 32,674,720Source | 42,221,808Source | 31,583,073Source | 23,796,000Source | 15,639,728Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 49,000Source | -617,000Source | 73,000Source | 3,706,000Source |
| General and Administrative ExpenseUSD | — | — | 5,231,000Source | 5,449,000Source | 6,417,000Source | 5,541,000Source | 5,938,000Source | 5,943,000Source | 22,569,000Source | 21,261,000Source | 16,640,000Source | 14,224,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -89,606,000Source | -87,466,000Source | -78,195,000Source | -96,781,000Source |
| Investment Income, InterestUSD | — | — | 634,000Source | 1,826,000Source | 1,093,000Source | 842,000Source | 1,250,000Source | 1,122,000Source | 4,017,000Source | 7,142,000Source | 6,400,000Source | 2,793,000Source |
| Nonoperating Income (Expense)USD | — | — | 628,000Source | 1,787,000Source | 1,143,000Source | 845,000Source | 1,194,000Source | 1,119,000Source | 4,006,000Source | 7,141,000Source | 6,213,000Source | 2,903,000Source |
| Operating ExpensesUSD | — | — | 18,654,000Source | 23,171,000Source | 18,939,000Source | 23,932,000Source | 18,942,000Source | 31,321,000Source | 93,612,000Source | 97,739,000Source | 84,766,000Source | 68,301,000Source |
| Research and Development ExpenseUSD | — | — | 13,423,000Source | 17,722,000Source | 12,522,000Source | 18,391,000Source | 13,004,000Source | 25,378,000Source | 71,043,000Source | 76,478,000Source | 68,126,000Source | 54,077,000Source |
Offerings
Registration 333-296016
Filing attachments
pepg-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 pepg-ex99_1.htm EX-99.1 EX-99.1 PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg - - 10 mg/kg FREEDOM2-DM1 cohort fully enrolled, with 7 of 8 participants having completed dosing; data expected in November - - Results from 12.5 mg/kg FREEDOM2-DM1 cohort expected in 1H 2027 - - Wel…
Read attachment ↗pepg-ex99_2.htm · 8-K · 2026-08-06
EX-99.2 3 pepg-ex99_2.htm EX-99.2 August 2026 Company Presentation Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressi…
Read attachment ↗d54577dex991.htm · 8-K · 2026-05-21
EX-99.1 2 d54577dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Company Presentation May 2026 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words…
Read attachment ↗pepg-ex99_1.htm · 8-K · 2026-05-12
EX-99.1 2 pepg-ex99_1.htm EX-99.1 EX-99.1 PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - FREEDOM2-DM1 5 mg/kg cohort demonstrated favorable safety, splicing and vHOT data, with the totality of results supporting the potential of the ongoing 10 mg/kg dose cohort - - The FREEDOM2 10 mg/kg cohort is fully enrolled, with data on track for 2H 2026 - - Well-funded with $132.3M of cash as of March 31, 2026, sufficient to fund operations through FREEDOM2 12…
Read attachment ↗pepg-ex99_1.htm · 8-K · 2026-03-30
EX-99.1 2 pepg-ex99_1.htm EX-99.1 EX-99.1 PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data - PGN-EDODM1 was generally well-tolerated with all adverse events mild or moderate and no serious adverse events reported - - Mean splicing correction of 7.3% observed with PGN-EDODM1 (n=6) versus 6.8% with placebo (n=2); Excluding one outlier patient, treatment group demonstrated mean …
Read attachment ↗pepg-ex99_2.htm · 8-K · 2026-03-30
EX-99.2 3 pepg-ex99_2.htm EX-99.2 March 2026 FREEDOM2-DM1 5 mg/kg MAD Cohort Data Update Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “on track,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variation…
Read attachment ↗